Free
Editorial Views  |   May 2016
A Slick Way Volatile Anesthetics Reduce Myocardial Injury
Author Notes
  • From the Department of Anesthesiology, Perioperative and Pain Medicine, School of Medicine, Stanford University, Stanford, California (N.-M.W., E.R.G.); VA San Diego Healthcare System, San Diego, California (H.H.P.); and Department of Anesthesiology, University of California, San Diego, La Jolla, California (H.H.P.).
  • Corresponding article on page 1065.
    Corresponding article on page 1065.×
  • Accepted for publication November 9, 2015.
    Accepted for publication November 9, 2015.×
  • Address correspondence to Dr. Patel: hepatel@ucsd.edu
Article Information
Editorial Views / Pharmacology
Editorial Views   |   May 2016
A Slick Way Volatile Anesthetics Reduce Myocardial Injury
Anesthesiology 5 2016, Vol.124, 986-988. doi:10.1097/ALN.0000000000001047
Anesthesiology 5 2016, Vol.124, 986-988. doi:10.1097/ALN.0000000000001047
Image: ©Thinkstock.
Image: ©Thinkstock.
Image: ©Thinkstock.
×
In 2007, the American College of Cardiology/American Heart Association guidelines first recommended perioperative volatile anesthetic use in patients at risk for myocardial ischemia.1  Numerous animal studies from canines to nematodes provided evidence for volatile anesthetic protection against myocardial ischemia–reperfusion injury.2,3  Several clinical trials conducted in patients undergoing coronary artery bypass grafting suggested the experimental study results translated into clinically relevant cardioprotection.4  However, almost a decade later, the primary molecular mechanisms mediating volatile anesthetic–induced cardioprotection still remain to be identified. In this month’s issue of Anesthesiology, Wojtovich et al.5  aim to provide novel insight into this limitation by deciphering the identity of a cardiac myocyte mitochondrial potassium channel that mediates volatile anesthetic–induced preconditioning. By using a genetic knock-out approach in mice, the authors identify the Slo2 gene family encoded potassium channel subtype Slo2.1 in cardiac myocyte mitochondria as a key determinant of volatile anesthetic–induced preconditioning from myocardial ischemia–reperfusion injury.5 
Both Slo2.1 (Kcnt2/’Slick’) and Slo2.2 (Kcnt1/’Slack’) are potassium channels activated by increased intracellular sodium levels and belong to the “big” conductance K+ channel (BK) family. The newly identified localization of Slick in cardiac myocyte mitochondria may add another piece to the puzzle of mitochondrial ion channels apparently involved in the complex response of cardiomyocytes to ischemia–reperfusion injury, including the mitochondrial ATP-sensitive K+ channel, the mitochondrial permeability transitional pore, and other BK channels that are long recognized in mediating volatile anesthetic–induced preconditioning via regulation of mitochondrial function.6  Although initial reports suggested that a Ca2+-activated BK channel (likely Slo1) was responsible for anesthetic preconditioning,7–9  the fact that Slo1−/− mice can still be preconditioned by isoflurane,10  coupled with the results of the study by Wojtovich et al., suggest reevaluation of these early findings.
In their present study, Wojtovich et al. report for the first time evidence that volatile anesthetic–induced K+ flux is abolished in cardiac myocyte mitochondria isolated from mice lacking Slick (Slo2.1−/−). Subsequently, isoflurane-induced preconditioning effects were absent in Slo2.1−/− mice but not in Slo2.2−/− mice subjected to myocardial ischemia–reperfusion injury. By demonstrating Slo2.1-mediated protective effects of volatile anesthetics that are independent of ischemia or pharmacologic K+ channel openers, the authors provide specificity for a novel molecular target for volatile anesthetic specific effects.
Thus, in the era of precision medicine, this study may provide us with more extensive knowledge to which patients undergoing cardiac surgery will benefit from receiving volatile anesthetics to reduce ischemia–reperfusion injury. The recommendations of the 2007 American College of Cardiology/American Heart Association guidelines have been continuously modified to downplay the powerful effects that volatile anesthetics have in reducing myocardial injury in preclinical models. In 2011, the recommendations for patients undergoing coronary artery bypass graft surgery were changed to only recommend the use of volatile anesthetics to facilitate extubation in cardiac patients.11  Further, the 2014 guidelines for patients undergoing noncardiac surgery recommend similarly the use of either volatile or intravenous agents.12  Primary endpoints such as a reduction in postoperative troponin levels or improved cardiac function were often met only in elective and highly selective cardiac patient populations4  and remained nonevident or controversial in patient populations undergoing noncardiac surgery.13,14  Numerous reasons may explain the clear lack of translation from experimental models to heterogeneous patient populations. Conditions such as diabetes likely attenuate the ability to precondition the myocardium and medications such as ATP-sensitive K+ channel channel inhibitors, used clinically to manage diabetes, may further block the effects of volatile anesthetics.14  Intravenous agents including opioids may also synergistically act with volatile anesthetics to reduce myocardial injury.15 
Advances in patient care are urgently needed to reduce perioperative myocardial reperfusion injury. Numerous preclinical studies provide a wealth of promising data on how volatile anesthetics or strategies like remote ischemic preconditioning effectively exert myocardial protection. Although the latter involves different mechanisms and requires additional molecular mediators,16  recently published results from two large studies show that remote ischemic conditioning strategies fail in providing benefit to patients.17,18  These data add to the litany of agents and interventions proposed to limit reperfusion injury that have failed in the clinic, including even cyclosporine A.19  The controversial data from clinical trials, however, must bring us back to better understand underlying molecular and cellular mechanisms in the basic science laboratory. Technology is moving in the direction where one day there may be a “preconditioning gene panel” that is run on every patient preoperatively to customize choice of anesthetic regimen for surgery. Candidate genes specific to volatile anesthetics, as that identified in the current manuscript, move us one step closer to identifying novel mechanisms to address the shortcomings of failed clinical translation.
Competing Interests
The authors are not supported by, nor maintain any financial interest in, any commercial activity that may be associated with the topic of this article.
References
Fleisher, LA, Beckman, JA, Brown, KA, Calkins, H, Chaikof, E, Fleischmann, KE, Freeman, WK, Froehlich, JB, Kasper, EK, Kersten, JR, Riegel, B, Robb, JF, Smith, SCJr, Jacobs, AK, Adams, CD, Anderson, JL, Antman, EM, Buller, CE, Creager, MA, Ettinger, SM, Faxon, DP, Fuster, V, Halperin, JL, Hiratzka, LF, Hunt, SA, Lytle, BW, Nishimura, R, Ornato, JP, Page, RL, Tarkington, LG, Yancy, CW American College of Cardiology/American Heart Association Task Force on Practice Guidelines (Writing Committee to Revise the 2002 Guidelines on Perioperative Cardiovascular Evaluation for Noncardiac Surgery); American Society of Echocardiography; American Society of Nuclear Cardiology; Heart Rhythm Society; Society of Cardiovascular Anesthesiologists; Society for Cardiovascular Angiography and Interventions; Society for Vascular Medicine and Biology; Society for Vascular Surgery, ACC/AHA 2007 guidelines on perioperative cardiovascular evaluation and care for noncardiac surgery: A report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines (Writing Committee to Revise the 2002 Guidelines on Perioperative Cardiovascular Evaluation for Noncardiac Surgery): Developed in collaboration with the American Society of Echocardiography, American Society of Nuclear Cardiology, Heart Rhythm Society, Society of Cardiovascular Anesthesiologists, Society for Cardiovascular Angiography and Interventions, Society for Vascular Medicine and Biology, and Society for Vascular Surgery.. Circulation. (2007). 116 e418–99 [Article] [PubMed]
Toller, WG, Gross, ER, Kersten, JR, Pagel, PS, Gross, GJ, Warltier, DC Sarcolemmal and mitochondrial adenosine triphosphate- dependent potassium channels: Mechanism of desflurane-induced cardioprotection.. Anesthesiology. (2000). 92 1731–9 [Article] [PubMed]
van Swinderen, B, Galifianakis, A, Crowder, M Common genetic determinants of halothane and isoflurane potencies in Caenorhabditis elegans.. Anesthesiology. (1998). 89 1509–17 [Article] [PubMed]
De Hert, SG Cardioprotection in anesthesia.. Minerva Anestesiol. (2008). 74 259–70 [PubMed]
Wojtovich, AP, Smith, CO, Urciuoli, WR, Wang, YT, Xia, X-M, Brookes, PS, Nehrke, K Cardiac Slo2.1 is required for volatile anesthetic stimulation of K+ transport and anesthetic preconditioning.. Anesthesiology. (2016). 124 1065–76
Agarwal, B, Stowe, DF, Dash, RK, Bosnjak, ZJ, Camara, AK Mitochondrial targets for volatile anesthetics against cardiac ischemia-reperfusion injury.. Front Physiol. (2014). 5 341 [Article] [PubMed]
Bentzen, BH, Osadchii, O, Jespersen, T, Hansen, RS, Olesen, SP, Grunnet, M Activation of big conductance Ca(2+)-activated K (+) channels (BK) protects the heart against ischemia-reperfusion injury.. Pflugers Arch. (2009). 457 979–88 [Article] [PubMed]
Redel, A, Lange, M, Jazbutyte, V, Lotz, C, Smul, TM, Roewer, N, Kehl, F Activation of mitochondrial large-conductance calcium-activated K+ channels via protein kinase A mediates desflurane-induced preconditioning.. Anesth Analg. (2008). 106 384–91 [Article] [PubMed]
Xu, W, Liu, Y, Wang, S, McDonald, T, Van Eyk, JE, Sidor, A, O’Rourke, B Cytoprotective role of Ca2+- activated K+ channels in the cardiac inner mitochondrial membrane.. Science. (2002). 298 1029–33 [Article] [PubMed]
Wojtovich, AP, Sherman, TA, Nadtochiy, SM, Urciuoli, WR, Brookes, PS, Nehrke, K SLO-2 is cytoprotective and contributes to mitochondrial potassium transport.. PLoS One. (2011). 6 e28287 [Article] [PubMed]
Hillis, LD, Smith, PK, Anderson, JL, Bittl, JA, Bridges, CR, Byrne, JG, Cigarroa, JE, Disesa, VJ, Hiratzka, LF, Hutter, AMJr, Jessen, ME, Keeley, EC, Lahey, SJ, Lange, RA, London, MJ, Mack, MJ, Patel, MR, Puskas, JD, Sabik, JF, Selnes, O, Shahian, DM, Trost, JC, Winniford, MD 2011 ACCF/AHA Guideline for Coronary Artery Bypass Graft Surgery: A report of the American College of Cardiology Foundation/American Heart Association Task Force on Practice Guidelines.. Circulation. (2011). 124 e652–735 [Article] [PubMed]
Fleisher, LA, Fleischmann, KE, Auerbach, AD, Barnason, SA, Beckman, JA, Bozkurt, B, Davila-Roman, VG, Gerhard-Herman, MD, Holly, TA, Kane, GC, Marine, JE, Nelson, MT, Spencer, CC, Thompson, A, Ting, HH, Uretsky, BF, Wijeysundera, DN American College of Cardiology; American Heart Association: 2014 ACC/AHA guideline on perioperative cardiovascular evaluation and management of patients undergoing noncardiac surgery: A report of the American College of Cardiology/American Heart Association Task Force on practice guidelines.. J Am Coll Cardiol. (2014). 64 e77–137 [Article] [PubMed]
Lindholm, EE, Aune, E, Norén, CB, Seljeflot, I, Hayes, T, Otterstad, JE, Kirkeboen, KA The anesthesia in abdominal aortic surgery (ABSENT) study: A prospective, randomized, controlled trial comparing troponin T release with fentanyl-sevoflurane and propofol-remifentanil anesthesia in major vascular surgery.. Anesthesiology. (2013). 119 802–12 [Article] [PubMed]
Zaugg, M, Lucchinetti, E, Behmanesh, S, Clanachan, AS Anesthetic cardioprotection in clinical practice from proof-of-concept to clinical applications.. Curr Pharm Des. (2014). 20 5706–26 [Article] [PubMed]
Ludwig, LM, Patel, HH, Gross, GJ, Kersten, JR, Pagel, PS, Warltier, DC Morphine enhances pharmacological preconditioning by isoflurane: Role of mitochondrial K(ATP) channels and opioid receptors.. Anesthesiology. (2003). 98 705–11 [Article] [PubMed]
Gross, ER, Hsu, AK, Urban, TJ, Mochly-Rosen, D, Gross, GJ Nociceptive-induced myocardial remote conditioning is mediated by neuronal gamma protein kinase C.. Basic Res Cardiol. (2013). 108 381 [Article] [PubMed]
Hausenloy, DJ, Candilio, L, Evans, R, Ariti, C, Jenkins, DP, Kolvekar, S, Knight, R, Kunst, G, Laing, C, Nicholas, J, Pepper, J, Robertson, S, Xenou, M, Clayton, T, Yellon, DM ERICCA Trial Investigators, Remote ischemic preconditioning and outcomes of cardiac surgery.. N Engl J Med. (2015). 373 1408–17 [Article] [PubMed]
Meybohm, P, Bein, B, Brosteanu, O, Cremer, J, Gruenewald, M, Stoppe, C, Coburn, M, Schaelte, G, Böning, A, Niemann, B, Roesner, J, Kletzin, F, Strouhal, U, Reyher, C, Laufenberg-Feldmann, R, Ferner, M, Brandes, IF, Bauer, M, Stehr, SN, Kortgen, A, Wittmann, M, Baumgarten, G, Meyer-Treschan, T, Kienbaum, P, Heringlake, M, Schön, J, Sander, M, Treskatsch, S, Smul, T, Wolwender, E, Schilling, T, Fuernau, G, Hasenclever, D, Zacharowski, K RIPHeart Study Collaborators, A multicenter trial of remote ischemic preconditioning for heart surgery.. N Engl J Med. (2015). 373 1397–407 [Article] [PubMed]
Cung, TT, Morel, O, Cayla, G, Rioufol, G, Garcia-Dorado, D, Angoulvant, D, Bonnefoy-Cudraz, E, Guérin, P, Elbaz, M, Delarche, N, Coste, P, Vanzetto, G, Metge, M, Aupetit, JF, Jouve, B, Motreff, P, Tron, C, Labeque, JN, Steg, PG, Cottin, Y, Range, G, Clerc, J, Claeys, MJ, Coussement, P, Prunier, F, Moulin, F, Roth, O, Belle, L, Dubois, P, Barragan, P, Gilard, M, Piot, C, Colin, P, De Poli, F, Morice, MC, Ider, O, Dubois-Randé, JL, Unterseeh, T, Le Breton, H, Béard, T, Blanchard, D, Grollier, G, Malquarti, V, Staat, P, Sudre, A, Elmer, E, Hansson, MJ, Bergerot, C, Boussaha, I, Jossan, C, Derumeaux, G, Mewton, N, Ovize, M Cyclosporine before PCI in patients with acute myocardial infarction.. N Engl J Med. (2015). 373 1021–31 [Article] [PubMed]
Image: ©Thinkstock.
Image: ©Thinkstock.
Image: ©Thinkstock.
×